Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Dairy, soy, and risk of breast cancer: those confounded milks https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyaa007/5743492#199259276 Dairy, soy, and risk of breast cancer: those confounded milks Gary E Fraser, Karen Jaceldo-Siegl, Michael Orlich, Andrew Mashchak, Rawiwan Sirirat, Synnove Knutsen International […]

Today, most people consume too much protein at dinner and not enough at breakfast. In recent years, scientific studies have shown that a balanced consumption of protein throughout the day […]

SAC Members and Research MD, PHD LaetitiaMichou Dr. Michou has completed her medicine studies at the University of Angers (France), her Rheumatology residency at the Denis Diderot-Paris VII University (France) […]

It is well known that calcium is a necessary nutrient because it plays an essential role in human health, not only for bone development but also for the heart, muscle […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

Available Volunteer Opportunities Call for Nominations – Board of Directors After evaluating the strengths of the existing Board of Directors, the Board Development Committee is seeking individuals with the following […]

The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

Our Senior Team Dr. Famida Jiwa President and CEO Dr. Jiwa is the President and CEO of Osteoporosis Canada, and has been with the organization since 2006. Prior to joining […]